Delving into the Latest Updates on Shanghai Laifu Life Science Technology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Cardiovascular Diseases

Respiratory Diseases

Mesenchymal stem cell therapy

CAR-T

Natural Killer Cell Therapies

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6

Top 5 Drug Type	Count

CAR-T	3
Mesenchymal stem cell therapy	2
Natural Killer Cell Therapies	1
Cell therapy	1
Monoclonal antibody	1

Top 5 Target	Count

CEA(Carcinoembryonic antigen)	1

Main objective: To explore the safety and tolerability of human umbilical cord mesenchymal stem cell injection in the treatment of interstitial lung disease (ILD); Secondary objective: To explore the preliminary effectiveness of human umbilical cord mesenchymal stem cell therapy for interstitial lung disease (ILD) and recommend appropriate cell therapy doses for subsequent clinical studies; Exploring the immunogenicity of human umbilical cord mesenchymal stem cell injection in the treatment of interstitial lung disease (ILD).

Start Date01 Oct 2025

Sponsor / Collaborator

Shanghai Laifu Life Science Technology Co., Ltd.

NCT05468502

/ RecruitingPhase 1

An Open Clinical Study to Explore the Safety, Tolerance and Preliminary Efficacy of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Main purpose
-To explore the safety and tolerance of human umbilical cord mesenchymal stem cells in the treatment of idiopathic pulmonary fibrosis (IPF).
Secondary purpose
* To explore the preliminary efficacy of human umbilical cord mesenchymal stem cells in the treatment of idiopathic pulmonary fibrosis (IPF), and to recommend the appropriate dose of cell therapy for subsequent clinical studies.
* To explore the immunogenicity of human umbilical cord mesenchymal stem cell injection in the treatment of idiopathic pulmonary fibrosis (IPF).
This study adopts a clinical research design of multi center, single dose and increasing dose.
18 qualified IPF subjects will be included in this study.

Start Date10 Oct 2022

Sponsor / Collaborator

Shanghai Laifu Life Science Technology Co., Ltd.

CTR20242448

/ Not yet recruitingPhase 1/2

探索人脐带间充质干细胞注射液治疗间质性肺病（ILD）的安全性、耐受性和初步有效性的I/II期临床试验

[Translation] A Phase I/II clinical trial to explore the safety, tolerability and preliminary efficacy of human umbilical cord mesenchymal stem cell injection in the treatment of interstitial lung disease (ILD)

I期主要目的：评价人脐带间充质干细胞注射液多次给药治疗ILD患者的安全性和耐受性，并确定最大耐受剂量（MTD）及II期推荐剂量（RP2D）。次要目的：评价人脐带间充质干细胞注射液多次给药治疗ILD患者的初步有效性和免疫原性。 II期的主要目的：评价人脐带间充质干细胞注射液治疗ILD患者的有效性。次要目的：评价人脐带间充质干细胞注射液治疗ILD患者的安全性和免疫原性。

[Translation]

The main purpose of Phase I is to evaluate the safety and tolerability of multiple administrations of human umbilical cord mesenchymal stem cell injection in the treatment of ILD patients, and to determine the maximum tolerated dose (MTD) and Phase II recommended dose (RP2D). Secondary purpose: to evaluate the preliminary efficacy and immunogenicity of multiple administrations of human umbilical cord mesenchymal stem cell injection in the treatment of ILD patients. The main purpose of Phase II is to evaluate the efficacy of human umbilical cord mesenchymal stem cell injection in the treatment of ILD patients. Secondary purpose: to evaluate the safety and immunogenicity of human umbilical cord mesenchymal stem cell injection in the treatment of ILD patients.

Start Date-

Sponsor / Collaborator

Shanghai Laifu Medical Technology Co., Ltd.

100 Clinical Results associated with Shanghai Laifu Life Science Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Laifu Life Science Technology Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Laifu Life Science Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Laifu Life Science Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 01 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

6

1

Preclinical

Phase 2

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Human Cord Derived MSC (Life science)	Pulmonary Disease, Chronic Obstructive More	IND Approval
LF-CAR-010	Solid tumor More	Preclinical
LF-MSC-GT010	Coronary Artery Disease More	Discovery
CN118184785 ( CEA )Patent Mining	Inflammation More	Discovery
LF-CAR-030	Solid tumor More	Discovery